ArticleCancers2024

Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study.

Yasin Kutlu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.